Manuscripts

Scientific manuscripts are developed in collaboration with key experts and are published in peer-reviewed journals.

This page is intended as an educational resource for U.S. healthcare professionals. The list of Acadia-sponsored manuscripts below may contain information about doses, uses, formulations, and populations different from product labeling or contain information about investigational compounds or uses not approved by the FDA. Please refer to the product’s Full Prescribing Information.

Showing 12 of 115 Results

November 18, 2024 Manuscript

Trofinetide benefits the ability to communicate in Rett syndrome: a plain language summary of the LAVENDER trial

Future Rare Diseases

August 7, 2024 Manuscript

Characterizing the journey of Rett syndrome among females in the United States: a real-world evidence study using the Rett syndrome natural history study database

Journal of Neurodevelopmental Disorders

July 17, 2024 Manuscript

Trofinetide for the treatment of Rett syndrome: Long-term safety and efficacy results of the 32-month, open-label LILAC-2 study

Med

July 15, 2024 Manuscript

Improvement in symptoms of Rett syndrome with trofinetide beyond clinical trial efficacy assessments: case reports

Future Rare Diseases

July 4, 2024 Manuscript

Effect of Hepatic Impairment on Trofinetide Exposures Using an In Silico Physiologically Based Pharmacokinetic Model

Advances in Therapy

June 24, 2024 Manuscript

Trofinetide for the treatment of Rett syndrome: Results from the open-label extension LILAC study

Med

June 13, 2024 Manuscript

Recommendations for the management of gastrointestinal comorbidities with or without trofinetide use in Rett syndrome

Expert Review of Gastroenterology & Hepatology

March 11, 2024 Manuscript

The effects of treatment with pimavanserin on activities of daily living in subjects with Parkinson’s disease psychosis (PDP): a 16-week open-label study

Therapeutic Advances in Neurological Disorders

March 11, 2024 Manuscript

Analysis of Medicare patients treated with pimavanserin versus other atypical antipsychotics: a cost-offset model evaluating skilled nursing facility stays and long-term care admissions in Parkinson’s disease psychosis

ClinicoEconomics and Outcomes Research

March 7, 2024 Manuscript

Safety profile of pimavanserin therapy in elderly patients with neurodegenerative disease-related neuropsychiatric symptoms: a phase 3B study

Journal of Alzheimer's Disease

March 1, 2024 Manuscript

Trofinetide treatment demonstrates a benefit over placebo for the ability to communicate in Rett syndrome

Pediatric Neurology

February 20, 2024 Manuscript

Managing gastrointestinal symptoms resulting from treatment with trofinetide for Rett syndrome: caregiver and nurse perspectives